Increased MicroRNA-1 and MicroRNA-133a Levels in Serum of Patients With Cardiovascular Disease Indicate Myocardial Damage

Abstract

Background-Recently, elevation of circulating muscle-specific microRNA (miRNA) levels has been reported in patients with acute myocardial infarction. However, it is still unclear from which part of the myocardium or under what conditions miRNAs are released into circulating blood. The purpose of this study was to identify the source of elevated levels of circulating miRNAs and their function in cardiovascular diseases. Methods and Results-Serum levels of miRNA (miR)-1 and miR-133a were increased significantly in patients not only with acute myocardial infarction but also with unstable angina pectoris and Takotsubo cardiomyopathy without elevation of serum creatine phosphokinase or cardiac troponin. MicroRNA microarray analysis of the heart from a mouse model of myocardial infarction indicated that the levels of miR-1, miR-133a, miR-208a, and miR-499 were significantly reduced in the infarcted myocardium. In situ hybridization of miR-133a also showed that miR-133a levels were very low in the infarcted and peri-infarcted myocardium. It has been shown that circulating miRNAs are localized inside exosomes, which are released after Ca 2ϩ stimulation. We stimulated H9c2 cardiomyoblasts with A23187 and measured miR-133a levels in the exosome fraction of the culture medium. A23187 induced a dose-dependent release of miR-133a, and significant elevation was observed only at concentrations where dead cells were detected. We also found that miR-133a-containing exosomes reduced the luciferase activity of 293FT cells transfected with an miR-133a sensor vector. Conclusions-These results suggest that elevated levels of circulating miR-133a in patients with cardiovascular diseases originate mainly from the injured myocardium. Circulating miR-133a can be used as a marker for cardiomyocyte death, and it may have functions in cardiovascular diseases. (Circ Cardiovasc Genet. 2011;4:446-454.)Key Words: circulating microRNA Ⅲ myocardial infarction Ⅲ cell death Ⅲ calcium ionophore M icroRNAs (miRNAs) are endogenous, single-stranded, Ϸ22-nucleotide noncoding RNAs. MicroRNAs are generally regarded as negative regulators of gene expression through inhibition of translation and/or promotion of mRNA degradation by base-pairing to complementary sequences within the 3Ј untranslated region (3ЈUTR) of protein-coding mRNA transcripts. 1 The first miRNA assigned to a specific function was lin-4, which targets lin-14 during temporal pattern formation in Caenorhabditis elegans. 2 Since then, a variety of miRNAs have been discovered. More than 500 miRNAs have been cloned and sequenced in humans, and the estimated number of miRNA genes may be as high as 1000 in the human genome. 3 Each miRNA regulates dozens to hundreds of distinct target genes; thus miRNAs are estimated to regulate the expression of more than one-third of human protein-coding genes. 4 Clinical Perspective on p 454The implications of miRNAs in the pathological process of the cardiovascular system have been recognized recently, and research on miRNAs in relation to cardiovascular dise...

MicroRNAs; easy and potent targets in optimizing therapeutic methods in reparative angiogenesis

“…Data also indicate that specific miRNAs such as miR‐130, ‐132, ‐133 are potentially interesting therapeutic targets that can be used to inhibit the initiation of the ischaemic‐induced pathological processes effects by acting on ECs and through VEGF and bFGF pathways 71, 86, 87, 99.…”

“…For example, after MI circulating miR‐1 and ‐133a released from exosomes can be taken up into other cells or organs for the induction of specific functions 87, 88, 89.…”

“…While circulating levels of miR‐1 and ‐133 are elevated, in patients with ischaemic cardiomyopathy or after MI, however, the expression levels of miR‐1 and ‐133 are diminished in diseased human heart 70, 82, 87, 90.…”

Circulating microRNAs: macro-utility as markers of prostate cancer?

“…Emerging evidence indicates that this stability is related to sequestration of extracellular miRNAs in various types of protective structures. First, miRNAs can be encapsulated in lipid vesicles, including exosomes (Valadi et al 2007, Kosaka et al 2010, Kuwabara et al 2011), microvesicles (Skog et al 2008, Zhang et al 2010b, and apoptotic bodies (Zernecke et al 2009). Secondly, miRNAs can be bound by RNA-binding proteins, including nucleophosmin 1 (NPM1; Wang et al 2010) and argonaute 2 (AGO2 (EIF2C2); Arroyo et al 2011).…”

“…Similarly, a subset of miRNAs is specifically released in exosomes from heart cells in response to myocardial infarction (Kuwabara et al 2011). Finally, recent evidence suggests that exosomal miRNA complexes are actively released in a process involving ceramide-dependent secretory machinery, with an enzyme involved in ceramide synthesis, neutral sphingomyelinase 2 (nSMase2 (SMPD3)), seemingly playing a key role (Kosaka et al 2010).…”